期刊文献+

消心痹方联合西药对肥厚型心肌病患者中医症状及左室功能的影响 被引量:7

The Effect of Xiaoxinbi Fang (消心痹方) Combined with Western Medicine on Chinese Medicine Symptoms and Left Ventricular Function in Patients with Hypertrophic Cardiomyopathy
原文传递
导出
摘要 目的观察消心痹方联合西药对肥厚型心肌病(HCM)的中医症状及对左室功能的影响。方法67例经彩色多普勒超声心动图证实的HCM患者随机分为对照组33例和治疗组34例。对照组给予倍他乐克缓释片47.5 mg口服,每日1次,根据血压、心率调整剂量治疗。治疗组在对照组治疗的基础上给予消心痹方口服,每日1剂。两组疗程均为90天。观察两组患者胸闷、胸痛、心悸、乏力、气短、头晕中医症状疗效,超声心动图检测两组患者治疗前后室间隔厚度(IVS)、左室后壁厚度(IVPW)及二者比值(IVS/IVPW)变化,检测两组治疗前后血浆NT-pro BNP并比较NYHA分级水平变化情况。结果治疗组治疗后胸痛、心悸、乏力、气短症状总有效率显著优于对照组(P<0.05)。两组治疗后NT-pro BNP含量均较本组治疗前明显降低(P<0.01);治疗组治疗后IVS、IVPW及IVS/LVPW均较治疗前显著降低(P<0.05);治疗组治疗后NT-pro BNP含量及IVS、IVPW、IVS/LVPW均明显低于对照组(P<0.05)。两组治疗后NYHA心功能分级均明显降低,且治疗组优于对照组(P<0.05)。结论消心痹方联合西药可以改善HCM患者临床症状,提高左室功能。 Objective To observe the effect of Xiaoxinbi Fang( 消心痹方) combined with western medicine on Chinese medicine symptoms and left ventricular function of hypertrophic cardiomyopathy( HCM). Methods Randomly divided 67 cases of patients with HCM proved by Color Doppler Echocardiography into a control group with 33 cases and a treatment group with 34 cases. The control group was given Betaloc sustained release tablets(47. 5 mg orally,once per day) and adjusted the dose according to blood pressure and heart rates. The treatment group was given Xiaoxinbi Fang in addition to the treatment of the control group,one dose per day. The treatment courses were both for 90 days. Observed curative effects of Chinese medicine symptoms,including chest distress,chest pain,heart palpitations,fatigue,shortness of breath and dizziness. Using echocardiography to examine the variation of interventricular septal thickness( IVS),left ventricular posterior wall thickness( IVPW) and their ratio( IVS / IVPW) before and after treatment. Examined NT-pro BNP content in plasma and compared the change of NYHA ranking level of both groups before and after treatment. Results The total effective rates of chest pain,heart palpitations,fatigue,shortness of breath of the treatment group after treatment was remarkably superior to those of the control group( P〈0. 05). The levels of NT-pro BNP in the two groups after treatment were both remarkably lower than those before treatment( P〈0. 01); IVS,IVPW and IVS / LVPW in the treatment group after treatment remarkably decreased compared with those before treatment( P〈0. 05); NT-pro BNP levels of the treatment group after treatment as well as IVS,IVPW and IVS / LVPW were all lower than those of the control group( P〈0. 05). NYHA cardiac functional grading in the two groups after treatment both remarkably decreased,with the treatment group superior to the control group( P〈0. 05). Conclusion Xiaoxinbi Fang combined with western medicine can improve clinical symptoms of patients with HCM and improve left ventricular function.
出处 《中医杂志》 CSCD 北大核心 2016年第15期1313-1316,共4页 Journal of Traditional Chinese Medicine
关键词 肥厚型心肌病 消心痹方 左室功能 hypertrophic cardiomyopathy Xiaoxinbi Fang(消心痹方) left ventricular function
作者简介 通讯作者:bettytime@163.com,13810123927
  • 相关文献

参考文献5

二级参考文献29

  • 1Yeo KTJ, Wu AHB,Apple FS, el al. Multicenter evaluation of the Roche NT- proBNP assay and comparison to the Biosite Triage BNP Assay[ J]. Clin Chem Acta,2003,338 : 107-115.
  • 2Pinto YM. Presented at 2nd International Symposium on NT-proBNP. Budapest, 2004,5 : 14-15.
  • 3Ng LL, Loke LW, Davies JE, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natrluretic peptides [ J ]. J Am Coll Cardiol,2005,45 : 1043-1050.
  • 4Lunchner A,Hengstenberg C, Lowel H, et al. Effect of compensated renal dysfunction on approved heart failure markers [ J ]. Hypertension, 2005,46 : 118- 123.
  • 5Yeo KTJ, Dumont KE, Timothy, et al. Elecsys NT-proBNP and BNP assays : are there analytically and clinically relevant differences [J] ? J Card Fail,2005,11 ( suppl 5) : S84-88.
  • 6Seino Y, Ogawa A, Yanmashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care : a more discerning marker for the detection and evalution of heart failure[ J]. Eur J Heart Fail,2004,6:295-300.
  • 7Rothenburger M, Wichter T, Schmid C, et al. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure[ J]. J Heart Lung Transplant,2004,7 : 1189-1197.
  • 8Groenning BA, Raymod I, Hildebrandt PR, et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population [ J ]. Heart ,2004,90:297-303.
  • 9Emdin M, Passino C, Prontera C, et al. Comparison of brain natriurefic peptide (BNP) and amio-terminal proBNP for early diagnosis of heart failure [ J ]. Clin Chem ,2007,53 (7) : 1289-1297.
  • 10McDongh TA, Holmer S, Raymod I, et al. NT-proBNP and the diagnosis of heart failure:a pool anlysis of three European epidemiological studies [ J ]. Eur J Heart Fail ,2004,6:269-273.

共引文献2817

同被引文献84

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部